je.st
news
Marina Biotech and Mirna Therapeutics Amend License Agreement for the ...
2014-01-03 03:24:21| Biotech - Topix.net
Under terms of the amendment, Mirna paid certain pre-payments to Marina Biotech and now has additional rights to its lead program, MRX34, currently in Phase 1 clinical development for patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
Tags: the
agreement
license
marina
Category:Biotechnology and Pharmaceuticals